Vigabatrin effect on inner retinal function.
OBJECTIVE
To determine the degree of electroretinal dysfunction in a group of patients taking Vigabatrin (VGB). Additionally, to investigate the role of cumulative dosage, the role of VGB alone or in combination with other anticonvulsants, and whether recent discontinuance of VGB affects electroretinal function as measured by the electroretinogram (ERG).


METHODS
Retrospective, comparative case series.


METHODS
Forty patients (18 male, 22 female) with a mean age of 35 years were studied as three groups: the VGB multitherapy group (n = 24) included those taking VGB with other anticonvulsants, the VGB monotherapy group (n = 9) included those taking VGB alone, and the off-VGB group (n = 7) included those who had discontinued VGB in the last 6 months.


METHODS
Scotopic flash, photopic flash, and 30-Hz flicker ERG results were recorded according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standard. The clinical electro-oculogram (EOG) results were recorded according to the ISCEV standard.


METHODS
Implicit time and amplitudes of the A- and B-waves of the flash and 30-Hz flicker ERGs were recorded. Summed amplitude of the first three oscillatory potential wavelets were recorded. The light-peak to-dark-trough Arden ratio of the EOG was evaluated.


RESULTS
Although photopic ERG B-wave reduction was most frequent in patients in the VGB multitherapy group (48% of eyes), a significant number of eyes in all three groups had scotopic ERG B-wave reduction. The 30-Hz flicker ERG result was abnormally reduced in all three groups. There was no significant difference in the frequency of occurrence in ERG result abnormalities between the VGB monotherapy and VGB multitherapy groups. The EOG results revealed reduced Arden ratios in all three groups; however, there was a significantly lower frequency of EOG abnormalities noted in the off-VGB group (P = 0. 0373). There was no statistically significant relationship between the frequency of electrodiagnostic abnormalities and the duration of use or the total cumulative dosage of Vigabatrin in any of the three groups.


CONCLUSIONS
These findings of scotopic ERG result abnormalities suggest that VGB alone has an effect on inner electroretinal function at the level of the Müller cell. Concomitant EOG abnormalities suggest a substantial effect of VGB on outer retinal function that may be reversible after cessation of VGB treatment.
Coupland
S G
SG
University of Ottawa Eye Institute, Ottawa, Ontario, Canada.
Zackon
D H
DH
Leonard
B C
BC
Ross
T M
TM
D000612:4-Aminobutyrate Transaminase / Q000037:antagonists & inhibitors; D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects*; D004585:Electrooculography / Q000187:drug effects; D004596:Electroretinography / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010775:Photic Stimulation; D012160:Retina / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology; D012164:Retinal Diseases / Q000139:chemically induced* / Q000201:enzymology / Q000503:physiopathology; D012189:Retrospective Studies; D020888:Vigabatrin / Q000009:adverse effects*
D000927:Anticonvulsants; D004791:Enzyme Inhibitors; D000612:4-Aminobutyrate Transaminase; D020888:Vigabatrin